Amgen (NASDAQ:AMGN) and CASI Pharmaceuticals (NASDAQ:CASI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.
Amgen pays an annual dividend of $5.80 per share and has a dividend yield of 2.5%. CASI Pharmaceuticals does not pay a dividend. Amgen pays out 40.3% of its earnings in the form of a dividend.
Amgen has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.
This table compares Amgen and CASI Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and target prices for Amgen and CASI Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Amgen presently has a consensus target price of $221.72, indicating a potential downside of 5.04%. CASI Pharmaceuticals has a consensus target price of $7.00, indicating a potential upside of 113.41%. Given CASI Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Amgen.
Institutional and Insider Ownership
76.6% of Amgen shares are owned by institutional investors. Comparatively, 11.3% of CASI Pharmaceuticals shares are owned by institutional investors. 0.3% of Amgen shares are owned by insiders. Comparatively, 24.3% of CASI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Amgen and CASI Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Amgen||$23.75 billion||5.84||$8.39 billion||$14.40||16.21|
|CASI Pharmaceuticals||N/A||N/A||-$27.47 million||($0.32)||-10.25|
Amgen has higher revenue and earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
Amgen beats CASI Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
Amgen Company Profile
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. It also markets other products in various markets, including Kyprolis, Nplate, Vectibix, Repatha, NEUPOGEN, Parsabiv, Blincyto, Aimovig, Imlygic, Corlanor, Kanjintitm, and Amgevitatm. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaborative agreements with Novartis; UCB; Bayer HealthCare Pharmaceuticals Inc.; and DaVita Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprises ZEVALIN, an ibritumomab tiuxetan injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-Hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-Hodgkin's lymphoma; and MARQIBO, a microtubule inhibitor to treat adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. In addition, the company engages in the development of a portfolio of 26 FDA-approved abbreviated new drug applications (ANDAs), including entecavir and tenofovir disoproxil fumarate indicated for hepatitis B virus; and 4 pipeline ANDAs that are pending FDA approval. Further, it is involved in developing ENMD-2076, an Aurora A/angiogenic kinase inhibitor that has completed Phase II studies for solid tumors, as well as various proprietary early-stage immune-oncological potential candidates in preclinical development. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.